Strategic Positioning
The only biotech company in China with publically declared focus to develop Treg immune therapy. A leader in IP driven Treg therapeutics.
Technologies & Product Innovations
Based our original discoveries and ensuing IPs on key Treg regulations, we are currently developing three series of products:
1. Topical ointment for mild to moderate psoriasis.
2. Small molecule oral medicine for IBD.
3. Treg cell therapy products.
All three technologies are based on our team’s own original IPs, using various techniques to produce Treg either via small molecule induction or genetic manipulations and being at the leading edge domestically and internationally.
Resources
Supported by a leading immunological research institution in China (Institute of Immunology, Tsinghua University, IITU) and its unsurpassed magnitude of clinical resources, the company is keenly aware of clinical needs. The combination provides the core drive and technical prowess to clinical translations.
 About Us
Benethera (Beijing) Biotechnologies, Inc. was founded in December 2021, and is situated at the Zhongguancun Biopharmaceutical Park in Haidian District, Beijing, and is a pre-clinical innovative immune cell therapy company.
描述
描述
描述
描述
描述
描述
描述
描述
描述
Cooperation
Units
XML 地图 | Sitemap 地图